...
...
Next Story

Remdesivir improves time to recovery in Covid-19 patients: Study

The study began on February 21, 2020 and enrolled 1,063 participants in 10 countries, with patients providing informed consent to participate, the researchers said.

Updated on: May 27, 2020, 12:46:10 IST
Press Trust of India | By
Prefer HTon Google
Advertisement

Remdesivir, the antiviral under clinical trials for treatment against novel coronavirus infection, is superior to the standard of care given to COVID-19 patients, according to a new study. The analysis, published in the New England Journal of Medicine, is based on data from the Adaptive COVID-19 Treatment Trial (ACTT), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) in the US.

FILE PHOTO: An ampule of Ebola drug Remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. Ulrich Perrey/Pool via REUTERS/File Photo (REUTERS)
FILE PHOTO: An ampule of Ebola drug Remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. Ulrich Perrey/Pool via REUTERS/File Photo (REUTERS)

In the randomised, controlled trial, clinicians enrolled adults hospitalised with COVID-19 who showed infection in the lower respiratory tract and suffered from moderate to severe disease. The researchers, including those from the New York University in the US, found that remdesivir was most beneficial for hospitalised patients with severe disease requiring supplemental oxygen. “Preliminary results of this trial suggest that a 10-day course of remdesivir was superior to placebo in the treatment of hospitalised patients with Covid-19,” the scientists wrote in the study.

Findings about benefits in other patient subgroups were less conclusive in this analysis, they said.

The study began on February 21, 2020 and enrolled 1,063 participants in 10 countries, with patients providing informed consent to participate, the researchers said. They said the patients were randomly assigned to receive local standard care and a 10-day course of the antiviral remdesivir intravenously, or local standard care and a placebo. According to the study, the trial was double-blind, meaning neither investigators nor participants knew who was receiving remdesivir or placebo.

The study defined recovery as being discharged from the hospital or being medically stable enough to be discharged from the hospital.

The median time for this, the researchers said, was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo. According to the study, the clinicians tracked patients’ health status daily using an eight-point ordinal scale ranging from fully recovered to death.

When the scientists compared clinical status between the study participants on day 15, they found that the odds of improvement in the ordinal scale were higher in the remdesivir arm than in the placebo arm of the trial. The study also suggested a survival benefit, with a 14-day mortality rate of 7 per cent for the group receiving remdesivir compared to nearly 12 per cent for the placebo group. However, the scientists noted that the difference in mortality was not statistically significant.

But they said the findings support remdesivir as the standard therapy for patients hospitalised with Covid-19, and requiring supplemental oxygen therapy.

The researchers said the mortality rate of 7 per cent at 14 days in the remdesivir arm indicated the need to evaluate antivirals with other therapeutic agents to continue to improve clinical outcomes for patients with Covid-19. “However, given high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is not likely to be sufficient,” the scientists noted in the study. PTI VIS VIS

 
ABOUT THE AUTHOR
HT News Desk

Follow the latest breaking news, major developments and agenda-setting stories from India and around the world with the newsdesk at Hindustan Times. Operating round the clock, the desk brings together experienced editors, reporters and correspondents to deliver fast, accurate and contextual reporting across subjects that influence public policy, governance, business, society and international affairs. The HT News Desk covers politics, elections, government policies, the economy, business and markets, science and technology, the environment, law and order, infrastructure, education, climate issues and geopolitics, while closely tracking developments across states, institutions and global capitals. The team also leads coverage of major breaking news events, policy announcements, court proceedings, natural disasters, public emergencies and significant international developments. Reports published by the newsdesk are based on information gathered from reporters on the ground, official statements, government agencies, court records, regulatory filings, recognised institutions and other authoritative sources. Stories undergo editorial scrutiny and verification processes to ensure accuracy, fairness and relevance, and are updated as events evolve and additional information becomes available. Whether covering a key political decision in New Delhi, an economic policy shift affecting millions, a landmark court ruling or a major global event, the HT News Desk aims to provide readers with reliable, fact-based journalism that delivers not only the latest developments but also the context and analysis needed to understand their wider implications.

Get the latest World News, breaking headlines, and real-time coverage from key global hotspots, including the US News, Russia, Ukraine, Iran News, and the UAE News. Track developing conflicts, high-stakes diplomacy, and major international events on Hindustan Times.
Get the latest World News, breaking headlines, and real-time coverage from key global hotspots, including the US News, Russia, Ukraine, Iran News, and the UAE News. Track developing conflicts, high-stakes diplomacy, and major international events on Hindustan Times.
SHARE THIS ARTICLE ON
Notifications

Get breaking alerts directly from the newsroom

Notifications are on!You'll be notified when news breaks